Research programme: second-generation diabetes/obesity therapeutics - InnodiaAlternative Names: ID 1135
Latest Information Update: 09 Mar 2009
At a glance
- Originator Innodia
- Developer BELLUS Health
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Mar 2007 Preclinical trials in Obesity in Canada (unspecified route)
- 06 Apr 2006 Preclinical trials in Type-2 diabetes mellitus in Canada (unspecified route)